Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
NEW YORK, Sept. 21, 2017 -- TG Therapeutics, Inc. (NASDAQ:TGTX) today announced its participation at two upcoming investor conferences. Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, is scheduled to present on Monday September 25, 2017 at 1:50pm ET at the Cantor Fitzgerald Global Healthcare Conference, being held at the InterContinental New York Barclay Hotel in New York City. Mr. Weiss is also scheduled to present on Tuesday, September 26, 2017 at 2:30pm ET at the Ladenburg Thalmann 2017 Healthcare Conference, being held at the Sofitel New York Hotel, also in New York City.
A live webcast of each presentation will be available on the Events page, located within the Investors & Media section, of the Company’s website at www.tgtherapeutics.com.
ABOUT TG THERAPEUTICS, INC.
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202 (umbralisib), an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B‐lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies, with TG-1101 also in clinical development for autoimmune disorders. The Company also has pre-clinical programs to develop IRAK4 inhibitors, BET inhibitors, and anti-PD-L1 and anti-GITR antibodies. TG Therapeutics is headquartered in New York City.
TGTX - G
CONTACT:
Jenna Bosco
Vice President- Investor Relations
TG Therapeutics, Inc.
Telephone: 212.554.4351
Email: [email protected]
